BTAI
NASDAQBioXcel Therapeutics Inc.
Price$0.75-0.38 (-33.86%)
2026-05-212026-08-25
News · 26 weeks47+700%
2026-03-012026-08-23
Mix1490d
- Insider6(43%)
- SEC Filings6(43%)
- Other2(14%)
Latest news
25 items- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- INSIDERSEC Form 4 filed by Director Atkins Susan E.4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERSEC Form 3 filed by new insider Atkins Susan E.3 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioXcel Therapeutics Inc.SCHEDULE 13G/A - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECSEC Form 10-Q filed by BioXcel Therapeutics Inc.10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- INSIDEROfficer Rodriguez Javier converted options into 35 shares, increasing direct ownership by 0.13% to 26,838 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 35 shares, increasing direct ownership by 0.13% to 26,335 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Scientific Officer Yocca Frank converted options into 35 shares, increasing direct ownership by 0.13% to 26,210 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERCEO and President Mehta Vimal converted options into 219 shares, increasing direct ownership by 0.31% to 69,817 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- PRBioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual MeetingNEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL. Positive primary results from the randomized, double-blind, placebo-controlled Phase 3 SERENITY At-Home safe
- INSIDERChief Scientific Officer Yocca Frank converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,175 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDEROfficer Rodriguez Javier converted options into 17,500 shares and sold $7,111 worth of shares (6,560 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 69% to 26,803 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 17,500 shares and sold $7,427 worth of shares (6,845 units at $1.08) as part of a pre-agreed trading plan, increasing direct ownership by 68% to 26,300 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERCEO and President Mehta Vimal converted options into 49,758 shares and sold $21,108 worth of shares (19,419 units at $1.09) as part of a pre-agreed trading plan, increasing direct ownership by 77% to 69,598 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- SECSEC Form 144 filed by BioXcel Therapeutics Inc.144 - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECSEC Form SCHEDULE 13G filed by BioXcel Therapeutics Inc.SCHEDULE 13G - BioXcel Therapeutics, Inc. (0001720893) (Subject)
- SECBioXcel Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- SECSEC Form 10-Q filed by BioXcel Therapeutics Inc.10-Q - BioXcel Therapeutics, Inc. (0001720893) (Filer)
- PRBioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial ResultsFDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company built on artificial intelligence ("AI") to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026. In the quarter ended on March 31, the
- INSIDERCEO and President Mehta Vimal converted options into 18,000 shares, increasing direct ownership by 85% to 39,259 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
- INSIDERChief Financial Officer Steinhart Richard I converted options into 9,000 shares, increasing direct ownership by 135% to 15,645 units (SEC Form 4)4 - BioXcel Therapeutics, Inc. (0001720893) (Issuer)
BTAI FAQ
7 questionsWhat does BioXcel Therapeutics Inc. do?
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA...Where does BTAI stock trade?
BioXcel Therapeutics Inc. (BTAI) is listed on NASDAQ.What sector and industry is BTAI in?
BioXcel Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BioXcel Therapeutics Inc. go public?
BioXcel Therapeutics Inc. (BTAI) completed its IPO in 2018.What are analysts saying about BTAI?
BioXcel Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Rodman & Renshaw: Buy with a $1700.00 price target on 2026-03-17.What companies are similar to BTAI?
Notable peers in the same industry include TPTX (Turning Point Therapeutics Inc.), TNYA (Tenaya Therapeutics Inc.), APLT (Applied Therapeutics Inc.), NBSE (NeuBase Therapeutics Inc.). Compare BTAI side-by-side with any of them on Quantisnow.How can I track BTAI on Quantisnow?
Quantisnow aggregates BioXcel Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BTAI to receive live email and push alerts on every new disclosure.